CD274 and myocarditis: Additionally, in a study of a combination of ICI with vascular endothelial growth factor receptor (VEGF) inhibitor axitinib plus anti-PD-L1 avelumab, despite the increase in median progression-free survival in patients with PD-L1-positive tumors, the study was discontinued due to death attributable to myocarditis in the combination group that was included [130].